The healthcare landscape is more complex than ever – and pharmaceutical companies are feeling the pressure. From pre-commercial drug development to post-launch performance, success hinges on a deep understanding of the full patient journey. However, traditional approaches to patient mapping often miss the nuanced factors that shape real-world health outcomes. Enter real-world data (RWD) enriched…

Cancer survival rates have improved dramatically over the past few decades thanks to ongoing advances in therapeutics. As research continues to push the boundaries of medicine, two innovative technologies stand out in the fight against cancer: Antibody-Drug Conjugates (ADCs) and PROteolysis TArgeting Chimeras (PROTACs). These cutting-edge approaches are refining how we treat cancer and opening…

For all the buzz around the Inflation Reduction Act (IRA), opinions on its impact are sharply divided – especially in the life sciences sector. Critics argue that the IRA’s drug pricing provisions, particularly Medicare price negotiation, will stifle innovation by reducing incentives for pharmaceutical companies to invest in research and development.  But these concerns don’t…

Nurse Practitioners (NPs) and Physician Assistants (PAs) are no longer just “support” staff for physicians. These clinicians are now taking on much bigger roles in patient care, including the ability to prescribe medications without physician oversight.  The COVID-19 pandemic accelerated the already growing trend of expanding NPs’ and PAs’ scope of practice. Now, five years…

The digital advertising landscape is shifting rapidly, and for healthcare and pharmaceutical marketers, the stakes are higher than ever. With evolving privacy regulations, increasing scrutiny on data practices and the challenge of balancing precision targeting with consumer protection, advertisers must rethink their strategies to stay effective and compliant. To tackle these pressing issues, PurpleLab recently…

The Give Kids a Chance Act of 2025 is a piece of legislation poised to transform drug development for children with rare diseases and cancer. Reintroduced in the House of Representatives on February 12, 2025, by Congressman Michael McCaul, this bipartisan effort aims to extend the Priority Review Voucher (PRV) program beyond its anticipated September…

A healthcare media agency wanted to increase awareness of their brand with additional direct to consumer (DTC), HIPAA and NAI compliant, privacy safe audiences. They wanted to drive prescriptions for consumers with migraines. The audiences needed to be applicable across channels and activatable on their preferred demand side platform (DSP).

A healthcare media agency wanted to increase awareness of their brand with additional direct to consumer (DTC), HIPAA and NAI compliant, privacy safe audiences. They wanted to drive prescriptions for consumers with migraines. The audiences needed to be applicable across channels and activatable on their preferred demand side platform (DSP).

Launching a new pharmaceutical product is a high-stakes endeavor, with nearly 40% of launches failing to meet expectations. To improve these odds, companies must shift to a data-driven approach, leveraging real-world insights to engage decision-makers effectively across the patient journey.